Sunshine Lake Pharma Files with CSRC to Convert 38.92 Million Domestic Shares into H Shares

Bulletin Express09-23

Sunshine Lake Pharma Co., Ltd. disclosed that it submitted a filing application to the China Securities Regulatory Commission (CSRC) on 23 September 2026 to commence an H-share full-circulation program. The plan involves converting 38.92 million domestic shares—approximately 6.75 % of the company’s total issued share capital—into H shares for listing and trading on the Main Board of The Stock Exchange of Hong Kong Limited.

The conversion and subsequent listing will proceed after the company secures all necessary approvals from the CSRC, the Hong Kong bourse, and other relevant regulators. Under the company’s articles of association and applicable PRC laws, the transaction does not require shareholder approval at a general meeting.

As of the announcement date, the CSRC has not yet accepted the filing, and detailed implementation steps remain pending. Sunshine Lake Pharma stated that further updates will be released in accordance with Hong Kong Listing Rules requirements. The company also cautioned shareholders and potential investors to exercise prudence when dealing in its securities until the regulatory process is complete.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment